Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Gilead Sciences Inc. announced an agreement with Compugen Ltd. to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503...